|
 Previous Article | Table of Contents | Next Article 
In vivo expression of the B7 costimulatory molecule by subsets of
antigen-presenting cells and the malignant cells of Hodgkin's disease
JM Munro, AS Freedman, JC Aster, JG Gribben, NC Lee, KK Rhynhart, J Banchereau and LM Nadler
Division of Tumor Immunology, Dana-Farber Cancer Institute, Boston, MA
02115.
The B-lymphocyte/accessory-cell activation antigen B7 (BB1) has been shown
in vitro to stimulate T-lymphocyte proliferation and cytokine production
via CD28 present on the latter cells. In this study, benign lymphoid
tissues, lymphomas, and extralymphoid inflammatory sites were examined
immunohistochemically using anti-B7 and other relevant monoclonal
antibodies. B7 was expressed by benign transformed germinal center B cells,
as it was by B cells of follicular lymphomas. B7 was also expressed by a
subpopulation (a mean of 31% to 65%) of macrophages and dendritic cells in
a variety of lymphoid tissues. It was present in abundance on all
macrophages constituting sarcoid granulomas in lymph nodes. In
extralymphoid inflammation, 17% to 35% of macrophages expressed B7 only
weakly. Cases of Hodgkin's disease showed expression of B7 by the majority
of Reed-Sternberg cells or malignant mononuclear variants, a phenomenon
that potentially contributes to the lymphocytic accumulation that is a
feature of this condition. CD28+ T cells were seen in all areas where T
cells were present. B7+ and CD28+ cells colocalized in, for example,
lymphoid follicles, lymph node paracortex, sarcoid granulomas, and
Hodgkin's disease tissue, indicating a potential for cellular interaction
via these molecules at these sites.
Volume 83,
Issue 3,
pp. 793-798,
02/01/1994
Copyright © 1994 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
J. Leonard, J. Friedberg, A Younes, D Fisher, L. Gordon, J Moore, M Czuczman, T Miller, P Stiff, B. Cheson, et al.
A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma
Ann. Onc.,
July 1, 2007;
18(7):
1216 - 1223.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S A Pileri, S Ascani, L Leoncini, E Sabattini, P L Zinzani, P P Piccaluga, A Pileri Jr, M Giunti, B Falini, G B Bolis, et al.
Hodgkin's lymphoma: the pathologist's viewpoint
J. Clin. Pathol.,
March 1, 2002;
55(3):
162 - 176.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Chen, K. Song, S. L. Eck, and Y. Chen
An Intra-Peyer's Patch Gene Transfer Model for Studying Mucosal Tolerance: Distinct Roles of B7 and IL-12 in Mucosal T Cell Tolerance
J. Immunol.,
September 15, 2000;
165(6):
3145 - 3153.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. K. Koski, G. N. Schwartz, D. E. Weng, R. E. Gress, F. H.C. Engels, M. Tsokos, B. J. Czerniecki, and P. A. Cohen
Calcium Ionophore-Treated Myeloid Cells Acquire Many Dendritic Cell Characteristics Independent of Prior Differentiation State, Transformation Status, or Sensitivity to Biologic Agents
Blood,
August 15, 1999;
94(4):
1359 - 1371.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. J. Freeman, A. A. Cardoso, V. A. Boussiotis, A. Anumanthan, R. W. Groves, T. S. Kupper, E. A. Clark, and L. M. Nadler
The BB1 Monoclonal Antibody Recognizes Both Cell Surface CD74 (MHC Class II-Associated Invariant Chain) as Well as B7-1 (CD80), Resolving the Question Regarding a Third CD28/CTLA-4 Counterreceptor
J. Immunol.,
September 15, 1998;
161(6):
2708 - 2715.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. M. Dorfman, J. L. Schultze, A. Shahsafaei, S. Michalak, J. G. Gribben, G. J. Freeman, G. S. Pinkus, and L. M. Nadler
In Vivo Expression of B7-1 and B7-2 By Follicular Lymphoma Cells Can Prevent Induction of T-Cell Anergy But Is Insufficient to Induce Significant T-Cell Proliferation
Blood,
December 1, 1997;
90(11):
4297 - 4306.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
